세계의 무세포 단백질 합성(CFPS) 시장(-2030년) : 제공 구분(세포 추출 시스템, 키트, 기기, 서비스), 워크플로우, 방법, 용도별

The cell-free protein synthesis market is projected to reach USD 308.9 million by 2030, up from USD 217.2 million in 2025, with a CAGR of 7.3% during the forecast period.

Growth in this market is driven by increasing demand for rapid and efficient protein production, rising adoption of reconstituted cell-free systems, expanding applications in synthetic biology and drug discovery, the need to express toxic and difficult-to-express proteins, and the integration of AI/ML to optimize expression systems.

The cell-free protein synthesis services experienced the fastest growth during the forecast period of 2025 to 2030.

The cell-free protein synthesis market is divided into offerings such as products-like expression systems, reagents, and instruments-and services. During the forecast period, cell-free protein synthesis services are expected to grow the fastest due to increasing demand for customized protein production solutions, the need for quick prototyping, and the rising adoption of outsourcing by academic institutions and biotech companies. These services enable researchers to access advanced CFPS technologies without investing in expensive infrastructure or expertise. Growing interest in contract-based protein expression for drug discovery, synthetic biology, vaccine development, and proteomics is fueling demand. Additionally, the increasing complexity of protein targets, including toxic, unstable, or membrane proteins, is encouraging more organizations to turn to specialized service providers who can deliver high-quality proteins quickly and efficiently.

Enzyme engineering is a key application of cell-free protein synthesis, dominating the CFPS market.

The CFPS market, categorized by application, includes enzyme engineering, high-throughput protein production, protein labeling, protein purification, and studies of protein-protein interactions. In 2024, enzyme engineering dominated the CFPS application market due to its extensive use in research areas like synthetic biology, pathway prototyping, directed evolution, and therapeutic antibody development. CFPS enables researchers to rapidly test and optimize enzymes without the need for living cells, making it ideal for designing enzymes with enhanced performance, stability, and specificity. Additionally, it supports the creation of new biocatalysts, improves metabolic pathways, and accelerates drug discovery. The increasing demand for faster, scalable, and flexible protein production in pharmaceuticals, biotechnology, and other sectors ensures that enzyme engineering will remain the primary growth driver in the CFPS market.

The Asia Pacific region will experience the highest CAGR in the cell-free protein synthesis market during the forecast period of 2025 to 2030.

Asia Pacific is projected to have the highest CAGR in the cell-free protein synthesis market during the forecast period, fueled by increasing investments in biotechnology research, growing pharmaceutical manufacturing, and a rising focus on synthetic biology and precision medicine in the region. Countries such as China, Japan, South Korea, and India are significantly boosting their R&D capabilities through government funding, public-private partnerships, and international collaborations, creating strong demand for CFPS technologies. The growing adoption of high-throughput protein production, enzyme engineering, and rapid prototyping in drug discovery, vaccine development, and diagnostics continues to drive market growth. Additionally, the region benefits from a large, skilled workforce, lower production costs, expanding contract research organizations (CROs), and improving research infrastructure, establishing Asia Pacific as a high-potential growth market for cell-free protein synthesis.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and (Executives) - 25%
• By Region: North America- 40%, Europe - 25%, Asia Pacific - 20%, Rest of the World - 15%

Promega Corporation (US), New England Biolabs (US), Thermo Fisher Scientific Inc. (US), Genscript (US), and Takara Bio Inc. (Japan) are among the major players in the cell-free protein synthesis market.

The study provides a detailed competitive analysis of these key players in the cell-free protein synthesis market, including their company profiles, recent updates, and main market strategies.

Research Coverage:

This research report categorizes the cell-free protein synthesis market by offering (products such as Expression Systems, Reagents, and Instruments), services, workflow stages (Template preparation, Reaction setup, Transcription and translation, Protein folding and post-translational modification, Recovery and purification, Validation and analysis), method (Coupled Transcription-Translation, Only Translation), application (Enzyme Engineering, High-Throughput Production, Protein Labeling, Protein Purification, Protein-Protein Interaction), end user (academic and research institutes, pharmaceutical and biotechnology companies, others), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report offers detailed information on key factors affecting the growth of the cell-free protein synthesis market, including drivers, trends, challenges, and opportunities. A comprehensive analysis of major industry players has been conducted to provide insights into their business profiles, products or services offered, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments such as new product launches and acquisitions within the cell-free protein synthesis market.

Key Benefits of Buying the Report:

The report will assist market leaders and newcomers by offering close estimates of revenue figures for the overall cell-free protein synthesis market and its segments. It will also help stakeholders better understand the competitive landscape and gain insights to more effectively position their business and develop appropriate go-to-market strategies. This report will allow stakeholders to grasp the market's current state and provide information on key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Increasing demand for rapid protein synthesis in research and pharma, growing demand for toxic and difficult-to-express proteins, integration of AI/ML for protein engineering using CFPS), restraints (high cost of essential reagents), opportunities (integration of cell-free technology in biosensors development, commercial-scale validation of cell-free protein expression) and challenges (Inability to fully replicate complex mammalian post-translational modifications) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services in the cell-free protein synthesis market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-free protein synthesis market
• Competitive Assessment: In-depth assessment of market share, growth strategies of leading players like New England Biolabs (US), Thermo Fisher Scientific Inc. (US), Takara Bio, Inc. (Japan), and Promega Corporation (US), among others, in the cell-free protein synthesis market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL CELL-FREE PROTEIN SYNTHESIS MARKET ESTIMATION, 2024
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary research
      • 2.2.1.3.1 Insights from primary experts
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN CELL-FREE PROTEIN SYNTHESIS MARKET
• 3.3 DISRUPTIVE TRENDS SHAPING CELL-FREE PROTEIN SYNTHESIS MARKET
• 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

• 4.1 GLOBAL CELL-FREE PROTEIN SYNTHESIS MARKET SNAPSHOT
• 4.2 NORTH AMERICA: CELL-FREE PROTEIN SYNTHESIS MARKET, BY APPLICATION AND COUNTRY, 2024
• 4.3 CELL-FREE PROTEIN SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 UNMET NEEDS & WHITE SPACES
• 4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing demand for rapid protein synthesis for research and therapeutic applications
    • 5.2.1.2 Momentum from biologics/ADC pipelines adopting CFPS for site-specific conjugation
    • 5.2.1.3 Ability to express difficult/complex proteins
  • 5.2.2 COMPARISON OF CONVENTIONAL LIVE CELLS AND CFPS SYSTEMS
  • 5.2.3 RESTRAINTS
    • 5.2.3.1 High cost of essential reagents
  • 5.2.4 OPPORTUNITIES
    • 5.2.4.1 Integration of cell-free technology in biosensor development
    • 5.2.4.2 Role in precision/personalized medicine
  • 5.2.5 CHALLENGES
    • 5.2.5.1 Inability to fully replicate complex mammalian post-translational modifications
    • 5.2.5.2 Concerns regarding scaling up
• 5.3 INDUSTRY TRENDS
  • 5.3.1 AI-GUIDED PROTEIN DESIGN PAIRED WITH CFPS FOR FASTER DISCOVERY
  • 5.3.2 SCALE-UP VIA CDMO PARTNERSHIPS TOWARD GMP READINESS
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER
  • 5.5.2 AVERAGE SELLING PRICE RANGE OF KEY PRODUCTS, BY REGION
  • 5.5.3 FACTORS IMPACTING CELL-FREE PROTEIN SYNTHESIS PRODUCT PRICING
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Cell-free protein synthesis (CFPS)
    • 5.6.1.2 Coupled transcription/translation
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Synthetic DNA/mRNA & IVT capping-tailing
    • 5.6.2.2 Membrane mimetics for CFPS
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Recombinant DNA Technology
• 5.7 TECHNOLOGY/PRODUCT ROADMAP
• 5.8 SUSTAINABILITY INITIATIVES
• 5.9 VALUE CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
  • 5.10.1 CELL-FREE PROTEIN SYNTHESIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 PATENT ANALYSIS
  • 5.12.1 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR CELL- FREE PROTEIN SYNTHESIS PATENTS
  • 5.12.2 LIST OF KEY PATENTS
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY FRAMEWORK
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.13.2.1 North America
    • 5.13.2.2 Europe
    • 5.13.2.3 Asia Pacific
    • 5.13.2.4 Rest of the World
• 5.14 KEY CONFERENCES & EVENTS
• 5.15 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA FOR CELL-FREE PROTEIN SYNTHESIS PRODUCTS
  • 5.15.3 ADOPTION BARRIER AND INTERNAL FRICTION
• 5.16 INVESTMENT/FUNDING ACTIVITY
• 5.17 IMPACT OF AI/GEN AI ON CELL-FREE PROTEIN SYNTHESIS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 AI USE CASES
  • 5.17.3 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM
• 5.18 IMPACT OF 2025 TRUMP TARIFF ON CELL-FREE PROTEIN SYNTHESIS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USERS
    • 5.18.5.1 Pharmaceutical & biotechnology companies
    • 5.18.5.2 Academic & research institutes
    • 5.18.5.3 CROs and CDMOs
    • 5.18.5.4 Diagnostic companies

6 CELL-FREE PROTEIN SYNTHESIS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 KITS & REAGENTS
    • 6.2.1.1 Increasing adoption in academic and commercial R&D to aid growth
  • 6.2.2 CELL EXTRACTS & EXPRESSION SYSTEMS
    • 6.2.2.1 Wheat germ
    • 6.2.2.2 Rabbit reticulocyte
    • 6.2.2.3 Mammalian
    • 6.2.2.4 Insect
    • 6.2.2.5 Plant/algal systems
  • 6.2.3 INSTRUMENTS
• 6.3 SERVICES

7 CELL-FREE PROTEIN SYNTHESIS MARKET, BY WORKFLOW

• 7.1 INTRODUCTION
• 7.2 REACTION SETUP
  • 7.2.1 USE OF CORE EXTRACTS IN THIS FOUNDATIONAL WORKFLOW STEP TO ACCELERATE ADOPTION
• 7.3 TRANSCRIPTION & TRANSLATION
  • 7.3.1 STRONG ADOPTION OF COUPLED TX/TL TO SUPPORT GROWTH
• 7.4 PROTEIN FOLDING/POST-TRANSLATIONAL MODIFICATIONS (PTMS)
  • 7.4.1 FOCUSING SHIFT TOWARDS COMPLEX TARGETS TO DRIVE SPENDING
• 7.5 TEMPLATE PREPARATION
  • 7.5.1 GROWTH IN OUTSOURCED AND IN-HOUSE DNA SYNTHESIS TO DRIVE GROWTH
• 7.6 RECOVERY & PURIFICATION
  • 7.6.1 READY-TO-RUN PURIFICATION MODULES CAN HELP VENDORS DIFFERENTIATE IN THE MARKET
• 7.7 VALIDATION & ANALYSIS
  • 7.7.1 IMPORTANT STEP TO CONFIRM EXPRESSION, PURITY, IDENTITY, AND FUNCTION, ALLOWING TEAMS TO MAKE GO/NO-GO DECISIONS

8 CELL-FREE PROTEIN SYNTHESIS MARKET, BY METHOD

• 8.1 INTRODUCTION
• 8.2 COUPLED TRANSCRIPTION/TRANSLATION (TX-TL) METHOD
  • 8.2.1 METHOD ENABLING SIMULTANEOUS SYNTHESIS OF MRNA AND PROTEIN IN SINGLE REACTION
• 8.3 TRANSCRIPTION & TRANSLATION
  • 8.3.1 TWO-STEP APPROACH SHORTENED DESIGN-TO-DATA PROCESS WHILE PROVIDING TIGHTER CONTROL OVER PRODUCT QUALITY

9 CELL-FREE PROTEIN SYNTHESIS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 ENZYME ENGINEERING
  • 9.2.1 RISING DEMAND FOR GREENER CHEMISTRIES TO AID GROWTH
• 9.3 HIGH THROUGHPUT PRODUCTION
  • 9.3.1 HT CFPS SET TO BECOME THE DEFAULT ENGINE FOR PARALLEL PROTOTYPING AND RAPID METHOD TRANSFER INTO DOWNSTREAM MANUFACTURING
• 9.4 PROTEIN-PROTEIN INTERACTION
  • 9.4.1 GROWING STUDIES DEMANDING PPI UNDERSTANDING AND COMPATIBILITY OF CFPS WITH MULTIPLEXED FORMATS TO AID GROWTH
• 9.5 PROTEIN LABELING
  • 9.5.1 DEMAND FOR SITE-SPECIFIC TAGS, AND RAPID ANALYTICS TO ACCELERATE ADOPTION
• 9.6 PROTEIN PURIFICATION
  • 9.6.1 RISE IN DEMAND FOR RAPID ACCESS TO PURIFIED PROTEINS TO SUPPORT GROWTH

10 CELL-FREE PROTEIN SYNTHESIS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 GROWING DEMAND FOR COMPRESSING TIMELINES AND EXPANDING COMPLEX BIOLOGICS TO DRIVE GROWTH
• 10.3 ACADEMIC RESEARCH INSTITUTES
  • 10.3.1 INCREASING DEMAND FOR INNOVATIVE RESEARCH SOLUTIONS TO SUPPORT GROWTH
• 10.4 CROS AND CDMOS
  • 10.4.1 FASTER STUDY CYCLES, AND STREAMLINING STUDY STARTS TO DRIVE SEGMENT
• 10.5 DIAGNOSTIC COMPANIES
  • 10.5.1 GROWING INTEREST IN CFPS-BASED DIAGNOSTICS FOR PATHOGEN OR BIOMARKER DETECTION TO SUPPORT GROWTH

11 CELL-FREE PROTEIN SYNTHESIS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 US
    • 11.2.1.1 Rising approvals of protein-based therapies and increasing investments in R&D to support growth
  • 11.2.2 CANADA
    • 11.2.2.1 Government funding for research and innovation to support market growth
• 11.3 EUROPE
  • 11.3.1 GERMANY
    • 11.3.1.1 Presence of major research institutes and pharmaceutical companies to support growth
  • 11.3.2 UK
    • 11.3.2.1 Strong commercial support for research & development work by government, especially in life sciences, to drive growth
  • 11.3.3 FRANCE
    • 11.3.3.1 Rise in proteomics research in France to support growth
  • 11.3.4 ITALY
    • 11.3.4.1 Growth in Italian market to be driven by increase in life science research projects
  • 11.3.5 SPAIN
    • 11.3.5.1 Presence of established network of research centers and universities, with collaborations in biomedicine & health and physical sciences & engineering, to support growth
  • 11.3.6 REST OF EUROPE (ROE)
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
    • 11.4.1.1 Growth in proteomics R&D and growing pharmaceutical industry to support growth
  • 11.4.2 JAPAN
    • 11.4.2.1 Increasing protein-based research to support market growth
  • 11.4.3 INDIA
    • 11.4.3.1 Increasing drug development outsourcing to support market growth
  • 11.4.4 AUSTRALIA
    • 11.4.4.1 Growing precision medicine research to offer significant growth opportunities in Australia
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Advancements in biopharmaceutical research and the development of novel therapies to support market growth
  • 11.4.6 REST OF ASIA PACIFIC (ROAPAC)
• 11.5 LATIN AMERICA
  • 11.5.1 BRAZIL
    • 11.5.1.1 Industrial investment in protein sector to support market growth
  • 11.5.2 MEXICO
    • 11.5.2.1 Growth in biotechnology and pharmaceutical sectors to support growth
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 GCC COUNTRIES
  • 11.6.2 REST OF MIDDLE EAST
  • 11.6.3 AFRICA
    • 11.6.3.1 Government investments in healthcare to drive market growth in region

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL-FREE PROTEIN SYNTHESIS MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Regional footprint
    • 12.5.5.3 Offering footprint
    • 12.5.5.4 Method footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 NEW ENGLAND BIOLABS
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products/ Services offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Expansions
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Key strengths
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses and competitive threats
  • 13.2.2 PROMEGA CORPORATION
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products/ Services offered
    • 13.2.2.3 MnM view
      • 13.2.2.3.1 Key strengths
      • 13.2.2.3.2 Strategic choices
      • 13.2.2.3.3 Weaknesses and competitive threats
  • 13.2.3 THERMO FISHER SCIENTIFIC INC.
    • 13.2.3.1 Business overview
    • 13.2.3.2 Products/ Services offered
    • 13.2.3.3 Recent developments
      • 13.2.3.3.1 Deals
    • 13.2.3.4 MnM view
      • 13.2.3.4.1 Key strengths
      • 13.2.3.4.2 Strategic choices
      • 13.2.3.4.3 Weaknesses and competitive threats
  • 13.2.4 GENSCRIPT
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products/ Services offered
  • 13.2.5 TAKARA BIO INC.
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products/ Services offered
  • 13.2.6 LENIOBIO GMBH
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products/ Services offered
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Deals
      • 13.2.6.3.2 Other developments
  • 13.2.7 CREATIVE BIOLABS
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products/ Services offered
  • 13.2.8 JENA BIOSCIENCE GMBH
    • 13.2.8.1 Business overview
    • 13.2.8.2 Products/ Services offered
  • 13.2.9 BIOTECHRABBIT
    • 13.2.9.1 Business overview
    • 13.2.9.2 Products/ Services offered
  • 13.2.10 BIODISCOVERY LLC
    • 13.2.10.1 Business overview
    • 13.2.10.2 Products/ Services offered
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Product launches
      • 13.2.10.3.2 Deals
  • 13.2.11 BIONEER CORPORATION
    • 13.2.11.1 Business overview
    • 13.2.11.2 Products/ Services offered
  • 13.2.12 SINO BIOLOGICAL, INC.
    • 13.2.12.1 Business overview
    • 13.2.12.2 Products/ Services offered
    • 13.2.12.3 Recent developments
      • 13.2.12.3.1 Deals
  • 13.2.13 KANEKA CORPORATION
    • 13.2.13.1 Business overview
    • 13.2.13.2 Products/ Services offered
    • 13.2.13.3 Recent developments
      • 13.2.13.3.1 Product launches
  • 13.2.14 GENECOPOEIA, INC.
    • 13.2.14.1 Business overview
    • 13.2.14.2 Products/ Services offered
  • 13.2.15 CELLFREE SCIENCES CO., LTD.
    • 13.2.15.1 Business overview
    • 13.2.15.2 Products/ Services offered
    • 13.2.15.3 Recent developments
      • 13.2.15.3.1 Deals
• 13.3 OTHER PLAYERS
  • 13.3.1 VECTORBUILDER INC.
  • 13.3.2 EXCELLGEN, INC.
  • 13.3.3 CD BIOSYNSIS
  • 13.3.4 CREATIVE BIOGENE
  • 13.3.5 CUSABIO TECHNOLOGY
  • 13.3.6 PROFACGEN
  • 13.3.7 CAYMAN CHEMICAL
  • 13.3.8 CAMBRIDGE ISOTOPE LABORATORIES, INC.
  • 13.3.9 SYNTHELIS BIOTECH
  • 13.3.10 SYNBIO TECHNOLOGIES
  • 13.3.11 AMSBIO

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS